New ADM Survey: Behaviors, Demands and Needs of Anti-Obesity Medications Users

Anti-obesity medications (AOMs) including GLP-1 receptor agonists have rapidly increased over the past year. According to Goldman Sachs Research, the global market for AOMs could reach $100 billion by 2030. With this surge in use, there is now a new sector of consumers with distinct needs.

Data from ADM's proprietary consumer insights platform, ADM Outside Voice℠, examines this swiftly growing segment, pinpointing how behaviors of US adult consumers engaging in AOMs have evolved.

Read more about the findings from ADM's newest survey here.